| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital (S.A.G., B.G., R.L., L.K.B., Y.E., L.P., M.A.T.); and Departments of Human Genetics (S.A.G., L.P., M.A.T.), Oncology (J.W.), Biology (L.P.), Medicine (L.P., M.A.T.), and Pediatrics (L.P.), McGill University, Montréal, Québec, Canada H3T 1E2
Address all correspondence and requests for reprints to: B. Gottlieb, Ph.D., Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote Ste. Catherine Road, Montreal, Quebec, Canada H3T 1E2. E-mail: bruce.gottlieb{at}mcgill.ca.
Five mutations in the ligand-binding domain (LBD) of the human androgen receptor (hAR) found in patients with varying degrees of androgen insensitivity syndrome (AIS) were investigated for their effects on receptor dynamics. These were Arg871Gly (mild), Ser814Asn (partial), Glu772Ala (partial), Val866Met (complete), and Arg774Cys (complete). Previous analysis showed that the mutant receptors exhibited near-normal kinetics, except Arg774Cys, which had severely reduced androgen binding, and Val866Met, which showed increased equilibrium dissociation constant (Kd) and elevated dissociation rate (k) values. Ser814Asn exhibited ligand-selective k values, i.e. increased for dihydrotestosterone and mibolerone, but normal for methyltrenolene.
Using mammalian two-hybrid assays, hAR amino/carboxyl (N/C)-terminal interactions of the mutant receptors were analyzed in the presence and absence of the hAR coactivator transcription intermediary factor 2 (TIF2). The mutations conferred decreased hAR N/C-terminal interaction, i.e. mild (
1.5-fold), partial (2-fold), and complete (10-fold), that mirrored the degree of AIS. All mutant LBDs showed a 2- to 3-fold increase in N/C-terminal interactions when TIF2 was cotransfected, although of a magnitude still less than that of wild-type LBD with TIF2.
The ligand-selective properties of the Ser814Asn mutant were also clearly reflected by the N/C-terminal interactions. Thus, measurement of N/C-terminal interactions may assist in the molecular analysis of mutant hARs associated with AIS.
Abbreviations: aa, Amino acids; AF, activation function; AIS, androgen insensitivity syndrome; CAIS, complete androgen insensitivity syndrome; DBD, DNA-binding domain; DHT, dihydrotestosterone; GAL, galactosidase; GRIP1, glucocorticoid receptor interacting protein 1; GSF, genital skin fibroblast; hAR, human androgen receptor; LBD, ligand-binding domain; Luc, luciferase; MAIS, mild androgen insensitivity syndrome; MB, mibolerone; MT, methyltrenolene; NTD, N-terminal domain; pCMV, cytomegalovirus promoter; pMMTV, mouse mammary tumor virus promoter; PR, progesterone receptor; pVP16, p virus transcriptional regulator protein 16; T, testosterone; SRC, steroid receptor coactivator; TIF2, transcription intermediary factor 2.
This article has been cited by other articles:
![]() |
Q. Ma, W. Fu, P. Li, S. V. Nicosia, G. Jenster, X. Zhang, and W. Bai FoxO1 Mediates PTEN Suppression of Androgen Receptor N- and C-Terminal Interactions and Coactivator Recruitment Mol. Endocrinol., February 1, 2009; 23(2): 213 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Centenera, J. M. Harris, W. D. Tilley, and L. M. Butler Minireview: The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling Mol. Endocrinol., November 1, 2008; 22(11): 2373 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Deeb, J. Jaaskelainen, M. Dattani, H. C. Whitaker, C. Costigan, and I. A. Hughes A Novel Mutation in the Human Androgen Receptor Suggests a Regulatory Role for the Hinge Region in Amino-Terminal and Carboxy-Terminal Interactions J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3691 - 3696. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bai and E. M. Wilson Epidermal Growth Factor-Dependent Phosphorylation and Ubiquitinylation of MAGE-11 Regulates Its Interaction with the Androgen Receptor Mol. Cell. Biol., March 15, 2008; 28(6): 1947 - 1963. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Askew, R. T. Gampe Jr., T. B. Stanley, J. L. Faggart, and E. M. Wilson Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone J. Biol. Chem., August 31, 2007; 282(35): 25801 - 25816. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kohler, A.-L. Delezoide, B. Boizet-Bonhoure, M. J McPhaul, C. Sultan, and S. Lumbroso Coexpression of Wilms' tumor suppressor 1 (WT1) and androgen receptor (AR) in the genital tract of human male embryos and regulation of AR promoter activity by WT1 J. Mol. Endocrinol., May 1, 2007; 38(5): 547 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Wilson Muscle-Bound? A Tissue-Selective Nonsteroidal Androgen Receptor Modulator Endocrinology, January 1, 2007; 148(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
J Jaaskelainen, A Deeb, J W Schwabe, N P Mongan, H Martin, and I A Hughes Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains. J. Mol. Endocrinol., April 1, 2006; 36(2): 361 - 368. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. A. Elhaji, I. Stoica, S. Dennis, E. O. Purisima, and M. A. Trifiro Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity Hum. Mol. Genet., March 15, 2006; 15(6): 921 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yoshikawa, K. Yamamoto, N. Shimizu, S. Yamada, C. Morimoto, and H. Tanaka The Distinct Agonistic Properties of the Phenylpyrazolosteroid Cortivazol Reveal Interdomain Communication within the Glucocorticoid Receptor Mol. Endocrinol., May 1, 2005; 19(5): 1110 - 1124. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Hsu, Y.-L. Chen, H.-J. Ting, W.-J. Lin, Z. Yang, Y. Zhang, L. Wang, C.-T. Wu, H.-C. Chang, S. Yeh, et al. Androgen Receptor (AR) NH2- and COOH-Terminal Interactions Result in the Differential Influences on the AR-Mediated Transactivation and Cell Growth Mol. Endocrinol., February 1, 2005; 19(2): 350 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Umar, C. A. Berrevoets, N. M. Van, M. van Leeuwen, M. Verbiest, W. J. Kleijer, D. Dooijes, J. A. Grootegoed, S. L. S. Drop, and A. O. Brinkmann Functional Analysis of a Novel Androgen Receptor Mutation, Q902K, in an Individual with Partial Androgen Insensitivity J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 507 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. A. Elhaji, J. Hui Wu, B. Gottlieb, L. K. Beitel, C. Alvarado, G. Batist, and M. A. Trifiro An Examination of How Different Mutations at Arginine 855 of the Androgen Receptor Result in Different Androgen Insensitivity Phenotypes Mol. Endocrinol., August 1, 2004; 18(8): 1876 - 1886. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |